Refine
Year of publication
- 2020 (16) (remove)
Has Fulltext
- yes (16)
Is part of the Bibliography
- no (16)
Keywords
- Advanced breast cancer (1)
- Anandamide (1)
- Antihormone therapy (1)
- Artificial Intelligence (1)
- Biodiversity Data (1)
- Biomonitoring (1)
- Botanical Collections (1)
- Brain tumors (1)
- CCL2 (1)
- Cancer (1)
- Children and adolescents (1)
- Cold hardiness (1)
- Cold tolerance (1)
- Compression stocking (1)
- Conservation (1)
- Deep vein thrombosis (1)
- Digitization (1)
- Distribution limits (1)
- HDAC4 (1)
- Herbaria (1)
- Heregulin (1)
- Inflammation (1)
- Leukemia (1)
- MM-121 (1)
- Metastatic (1)
- NCoR1 (1)
- Overwintering (1)
- Patient reported outcomes (1)
- Phenotypic plasticity (1)
- Pulmonary embolism (1)
- RBC (1)
- Research Infrastructure (1)
- Sarcomas (1)
- Semantics (1)
- Seribantumab (1)
- Social participation (1)
- Sub-zero exposure (1)
- Taxonomy (1)
- Venous thromboembolism (1)
- Winter survival (1)
- acute myeloid leukaemia (1)
- archeological modeling (1)
- cancer (1)
- human–environment interaction (1)
- image-based risk modelling (1)
- induction chemotherapy (1)
- machine learning (1)
- open science (1)
- paleoclimate modeling (1)
- paleoenvironment modeling (1)
- paleoenvironment reconstruction (1)
- pancreatic cancer (1)
- personalised therapy (1)
- radiation oncology (1)
- radiomic (1)
- transfusion (1)
In this report, we present the contributions, outcomes, ideas, discussions and conclusions obtained at the PaleoMaps Workshop 2019, that took place at the Institute of Geography of the University of Cologne on 23 and 24 September 2019. The twofold aim of the workshop was: (1) to provide an overview of approaches and methods that are presently used to incorporate paleoenvironmental information in human–environment interaction modeling applications, and building thereon; (2) to devise new approaches and solutions that might be used to enhance the reconstruction of past human–environmental interconnections. This report first outlines the presented papers, and then provides a joint protocol of the often extensive discussions that came up following the presentations or else during the refreshment intervals. It concludes by adressing the open points to be resolved in future research avenues, e.g., implementation of open science practices, new procedures for reviewing of publications, and future concepts for quality assurance of the often complex paleoenvironmental data. This report may serve as an overview of the state of the art in paleoenvironment mapping and modeling. It includes an extensive compilation of the basic literature, as provided by the workshop attendants, which will itself facilitate the necessary future research.
Plants, fungi and algae are important components of global biodiversity and are fundamental to all ecosystems. They are the basis for human well-being, providing food, materials and medicines. Specimens of all three groups of organisms are accommodated in herbaria, where they are commonly referred to as botanical specimens.The large number of specimens in herbaria provides an ample, permanent and continuously improving knowledge base on these organisms and an indispensable source for the analysis of the distribution of species in space and time critical for current and future research relating to global biodiversity. In order to make full use of this resource, a research infrastructure has to be built that grants comprehensive and free access to the information in herbaria and botanical collections in general. This can be achieved through digitization of the botanical objects and associated data.The botanical research community can count on a long-standing tradition of collaboration among institutions and individuals. It agreed on data standards and standard services even before the advent of computerization and information networking, an example being the Index Herbariorum as a global registry of herbaria helping towards the unique identification of specimens cited in the literature.In the spirit of this collaborative history, 51 representatives from 30 institutions advocate to start the digitization of botanical collections with the overall wall-to-wall digitization of the flat objects stored in German herbaria. Germany has 70 herbaria holding almost 23 million specimens according to a national survey carried out in 2019. 87% of these specimens are not yet digitized. Experiences from other countries like France, the Netherlands, Finland, the US and Australia show that herbaria can be comprehensively and cost-efficiently digitized in a relatively short time due to established workflows and protocols for the high-throughput digitization of flat objects.Most of the herbaria are part of a university (34), fewer belong to municipal museums (10) or state museums (8), six herbaria belong to institutions also supported by federal funds such as Leibniz institutes, and four belong to non-governmental organizations. A common data infrastructure must therefore integrate different kinds of institutions.Making full use of the data gained by digitization requires the set-up of a digital infrastructure for storage, archiving, content indexing and networking as well as standardized access for the scientific use of digital objects. A standards-based portfolio of technical components has already been developed and successfully tested by the Biodiversity Informatics Community over the last two decades, comprising among others access protocols, collection databases, portals, tools for semantic enrichment and annotation, international networking, storage and archiving in accordance with international standards. This was achieved through the funding by national and international programs and initiatives, which also paved the road for the German contribution to the Global Biodiversity Information Facility (GBIF).Herbaria constitute a large part of the German botanical collections that also comprise living collections in botanical gardens and seed banks, DNA- and tissue samples, specimens preserved in fluids or on microscope slides and more. Once the herbaria are digitized, these resources can be integrated, adding to the value of the overall research infrastructure. The community has agreed on tasks that are shared between the herbaria, as the German GBIF model already successfully demonstrates.We have compiled nine scientific use cases of immediate societal relevance for an integrated infrastructure of botanical collections. They address accelerated biodiversity discovery and research, biomonitoring and conservation planning, biodiversity modelling, the generation of trait information, automated image recognition by artificial intelligence, automated pathogen detection, contextualization by interlinking objects, enabling provenance research, as well as education, outreach and citizen science.We propose to start this initiative now in order to valorize German botanical collections as a vital part of a worldwide biodiversity data pool.
Background: Eligibility criteria are a critical part of clinical trials, as they define the patient population under investigation. Besides certain patient characteristics, clinical trials often include biomarker testing for eligibility. However, patient-identification mostly relies on the trial site itself and is often a time-consuming procedure, which could result in missing out on potentially eligible patients. Pre-selection of those patients using a registry could facilitate the process of eligibility testing and increase the number of identified patients. One aim with the PRAEGNANT registry (NCT02338167) is to identify patients for therapies based on clinical and molecular data. Here, we report eligibility testing for the SHERBOC trial using the German PRAEGNANT registry.
Methods:Heregulin (HRG) has been reported to identify patients with better responses to therapy with the anti-HER3 monoclonal antibody seribantumab (MM-121). The SHERBOC trial investigated adding seribantumab (MM-121) to standard therapy in patients with advanced HER2-negative, hormone receptor–positive (HR-positive) breast cancer and HRG overexpression. The PRAEGNANT registry was used for identification and tumor testing, helping to link potential HRG positive patients to the trial. Patients enrolled in PRAEGNANT have invasive and metastatic or locally advanced, inoperable breast cancer. Patients eligible for SHERBOC were identified by using the registry. Study aims were to describe the HRG positivity rate, screening procedures, and patient characteristics associated with inclusion and exclusion criteria.
Results: Among 2769 unselected advanced breast cancer patients, 650 were HER2-negative, HR-positive and currently receiving first- or second-line treatment, thus potentially eligible for SHERBOC at the end of current treatment; 125 patients also met further clinical eligibility criteria (e.g. menopausal status, ECOG). In the first/second treatment lines, patients selected for SHERBOC based on further eligibility criteria had a more favorable prognosis than those not selected. HRG status was tested in 38 patients, 14 of whom (36.8%) proved to be HRG-positive.
Conclusion: Using a real-world breast cancer registry allowed identification of potentially eligible patients for SHERBOC focusing on patients with HER3 overexpressing, HR-positive, HER2-negative metastatic breast cancer. This approach may provide insights into differences between patients eligible or non-eligible for clinical trials.
Trial registration: Clinicaltrials, NCT02338167, Registered 14 January 2015 - retrospectively registered.
In this paper we present first-order reversal curve (FORC) diagrams of ensembles of three-dimensional Co3Fe nanostructures as 2 × 2 arrays of nano-cubes and nano-trees. The structures are fabricated and investigated by an advanced platform of focused electron beam induced deposition combined with high-resolution detection of magnetic stray fields using a home-built micro-Hall magnetometer based on an AlGaAs/GaAs heterostructure. The experimental FORC diagrams are compared to macrospin simulations for both geometries at different angles of the externally applied magnetic field. The measured FORC diagrams are in good agreement with the simulated ones and reflect non-uniform magnetization reversal dominated by multi-vortex states within, and strong magnetic coupling between, the building blocks of our nanostructures. Thus, a FORC analysis of small arrays of 3D magnetic nanostructures provides more detailed insights into the mechanisms of magnetization reversal beyond standard major hysteresis loop measurements.
Für die Zukunftsfähigkeit des Mittelstandes ist es von großer Bedeutung, dass Betriebe über ausreichend und gut qualifizierte Fach- und Arbeitskräfte verfügen. Die Roadmap KMU. Kompetent. stellt ein Instrument dar, damit Geschäftsführer*innen und Personalverantwortliche für ihre wichtige Personalarbeit die passgenaue Unterstützung erhalten können. Das Instrument der Roadmap schafft in einem ersten Schritt Transparenz darüber, welche Angebote und Ansprechpartner*innen zur Unterstützung von Personalverantwortlichen schon vorhanden sind und wo noch Handlungsbedarfe bestehen. Daran kann vor Ort angeknüpft und weitere Angebote und Ansprechpartner*innen ergänzt werden.
Mithilfe dieser Roadmap sollen einerseits Bertriebe einen einfach zugänglichen Überblick über regionale und überregionale Angebote und Ansprechpartner*innen erhalten und andererseits regionale Akteure vernetzt darauf einwirken können, dass Personalverantwortliche in kleinen und mittelgroßen Betrieben auch zukünftig ihre wichtige Personalarbeit, gut unterstützt und begleitet, leisten können.
Für die Zukunftsfähigkeit des Mittelstandes ist es von großer Bedeutung, dass Betriebe über ausreichend und gut qualifizierte Fach- und Arbeitskräfte verfügen. Die Roadmap KMU. Kompetent. stellt ein Instrument dar, damit Geschäftsführer*innen und Personalverantwortliche für ihre wichtige Personalarbeit die passgenaue Unterstützung erhalten können. Das Instrument der Roadmap schafft in einem ersten Schritt Transparenz darüber, welche Angebote und Ansprechpartner*innen zur Unterstützung von Personalverantwortlichen schon vorhanden sind und wo noch Handlungsbedarfe bestehen. Daran kann vor Ort angeknüpft und weitere Angebote und Ansprechpartner*innen ergänzt werden.
Mithilfe dieser Roadmap sollen einerseits Bertriebe einen einfach zugänglichen Überblick über regionale und überregionale Angebote und Ansprechpartner*innen erhalten und andererseits regionale Akteure vernetzt darauf einwirken können, dass Personalverantwortliche in kleinen und mittelgroßen Betrieben auch zukünftig ihre wichtige Personalarbeit, gut unterstützt und begleitet, leisten können.
Background Polypharmacy interventions are resource-intensive and should be targeted to those at risk of negative health outcomes. Our aim was to develop and internally validate prognostic models to predict health-related quality of life (HRQoL) and the combined outcome of falls, hospitalisation, institutionalisation and nursing care needs, in older patients with multimorbidity and polypharmacy in general practices.
Methods Design: two independent data sets, one comprising health insurance claims data (n=592 456), the other data from the PRIoritising MUltimedication in Multimorbidity (PRIMUM) cluster randomised controlled trial (n=502). Population: ≥60 years, ≥5 drugs, ≥3 chronic diseases, excluding dementia. Outcomes: combined outcome of falls, hospitalisation, institutionalisation and nursing care needs (after 6, 9 and 24 months) (claims data); and HRQoL (after 6 and 9 months) (trial data). Predictor variables in both data sets: age, sex, morbidity-related variables (disease count), medication-related variables (European Union-Potentially Inappropriate Medication list (EU-PIM list)) and health service utilisation. Predictor variables exclusively in trial data: additional socio-demographics, morbidity-related variables (Cumulative Illness Rating Scale, depression), Medication Appropriateness Index (MAI), lifestyle, functional status and HRQoL (EuroQol EQ-5D-3L). Analysis: mixed regression models, combined with stepwise variable selection, 10-fold cross validation and sensitivity analyses.
Results Most important predictors of EQ-5D-3L at 6 months in best model (Nagelkerke’s R² 0.507) were depressive symptoms (−2.73 (95% CI: −3.56 to −1.91)), MAI (−0.39 (95% CI: −0.7 to −0.08)), baseline EQ-5D-3L (0.55 (95% CI: 0.47 to 0.64)). Models based on claims data and those predicting long-term outcomes based on both data sets produced low R² values. In claims data-based model with highest explanatory power (R²=0.16), previous falls/fall-related injuries, previous hospitalisations, age, number of involved physicians and disease count were most important predictor variables.
Conclusions Best trial data-based model predicted HRQoL after 6 months well and included parameters of well-being not found in claims. Performance of claims data-based models and models predicting long-term outcomes was relatively weak. For generalisability, future studies should refit models by considering parameters representing well-being and functional status.
Background:Aedes aegypti is a potential vector for several arboviruses including dengue and Zika viruses. The species seems to be restricted to subtropical/tropical habitats and has difficulties in establishing permanent populations in southern Europe, probably due to constraints during the winter season. The aim of this study was to systematically analyze the cold tolerance (CT) of Ae. aegypti in its most cold-resistant life stage, the eggs.
Methods: The CT of Ae. aegypti eggs was compared with that of Ae. albopictus which is well established in large parts of Europe. By systematically studying the literature (meta-analysis), we recognized that CT has been rarely tested in Ae. aegypti eggs, but eggs can survive at zero and sub-zero temperatures for certain exposure periods. To overcome potential bias from experimental differences between studies, we then conducted species comparisons using a harmonized high-resolution CT measuring method. From subtropical populations of the same origin, the survival (hatching in %) and emergence of adults of both species were measured after zero and sub-zero temperature exposures for up to 9 days (3 °C, 0 °C and − 2 °C: ≤ 9 days; − 6 °C: ≤ 2 days).
Results: Our data show that Ae. aegypti eggs can survive low and sub-zero temperatures for a short time period similar to or even better than those of Ae. albopictus. Moreover, after short sub-zero exposures of eggs of both species, individuals still developed into viable adults (Ae. aegypti: 3 adults emerged after 6 days at − 2 °C, Ae. albopictus: 1 adult emerged after 1 day at − 6 °C).
Conclusions: Thus, both the literature and the present experimental data indicate that a cold winter may not be the preventing factor for the re-establishment of the dengue vector Ae. aegypti in southern Europe.
Für die Zukunftsfähigkeit des Mittelstandes ist es von großer Bedeutung, dass Betriebe über ausreichend und gut qualifizierte Fach- und Arbeitskräfte verfügen. Die Roadmap KMU. Kompetent. stellt ein Instrument dar, damit Geschäftsführer*innen und Personalverantwortliche für ihre wichtige Personalarbeit die passgenaue Unterstützung erhalten können. Das Instrument der Roadmap schafft in einem ersten Schritt Transparenz darüber, welche Angebote und Ansprechpartner*innen zur Unterstützung von Personalverantwortlichen schon vorhanden sind und wo noch Handlungsbedarfe bestehen. Daran kann vor Ort angeknüpft und weitere Angebote und Ansprechpartner*innen ergänzt werden.
Mithilfe dieser Roadmap sollen einerseits Bertriebe einen einfach zugänglichen Überblick über regionale und überregionale Angebote und Ansprechpartner*innen erhalten und andererseits regionale Akteure vernetzt darauf einwirken können, dass Personalverantwortliche in kleinen und mittelgroßen Betrieben auch zukünftig ihre wichtige Personalarbeit, gut unterstützt und begleitet, leisten können.
Objective: Pancreatic ductal adenocarcinoma (PDAC) still carries a dismal prognosis with an overall 5-year survival rate of 9%. Conventional combination chemotherapies are a clear advance in the treatment of PDAC; however, subtypes of the disease exist, which exhibit extensive resistance to such therapies. Genomic MYC amplifications represent a distinct subset of PDAC with an aggressive tumour biology. It is clear that hyperactivation of MYC generates dependencies that can be exploited therapeutically. The aim of the study was to find and to target MYC-associated dependencies.
Design: We analysed human PDAC gene expression datasets. Results were corroborated by the analysis of the small ubiquitin-like modifier (SUMO) pathway in a large PDAC cohort using immunohistochemistry. A SUMO inhibitor was used and characterised using human and murine two-dimensional, organoid and in vivo models of PDAC.
Results: We observed that MYC is connected to the SUMOylation machinery in PDAC. Components of the SUMO pathway characterise a PDAC subtype with a dismal prognosis and we provide evidence that hyperactivation of MYC is connected to an increased sensitivity to pharmacological SUMO inhibition.
Conclusion: SUMO inhibitor-based therapies should be further developed for an aggressive PDAC subtype.